Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Information source: Mie University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Adrenal Tumors
Intervention: Radiofrequency ablation (Procedure)
Phase: Phase 2/Phase 3
Sponsored by: Mie University
Official(s) and/or principal investigator(s):
Koichiro Yamakado, MD, Study Chair, Affiliation: Mie University School of Medicine
The purpose of this study is to evaluate changes in adrenal hormones during adrenal
radiofrequency (RF) ablation.
Official title: Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Increase in Catecholamine
Serum Cathecholamine Levels
Number of Participants With Hypertension During Adrenal or Non-adrenal Radiofrequency Ablation
Secondary outcome: Increase in Cortisol
Adrenal radiofrequency (RF) ablation has been increasingly used for the treatment of
unresectable adrenal tumors. But one of the major complication is a increase in blood
pressure. Hormonal release during RF ablation is considered the cause of hypertension. But
there has been no evidence that adrenal hormones affects changes in blood pressure. In this
prospective study, we evaluate the changes in adrenal hormones during RF ablation and
clarify the cause of hypertensive crisis.
Minimum age: 20 Years.
Maximum age: N/A.
- Unresectable adrenal tumor which will be treated by radiofrequency (RF)ablation
- Blood pressure is 140mmHg or less before RF ablation
- Age of 20-years or more
- Performance status of 0 or 1
- Agreement from the patient
- Platelet count of 50,000/mm^3 or International normalized ratio (INR)>1. 5
Locations and Contacts
Mie University, Tsu, Mie 514-8507, Japan
Mie University Hospital, Tsu, Mie 514-8507, Japan
Starting date: October 2009
Last updated: April 6, 2015